Short Interest in Cytosorbents Co. (NASDAQ:CTSO) Grows By 5.5%

Cytosorbents Co. (NASDAQ:CTSO - Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,930,000 shares, an increase of 5.5% from the January 15th total of 1,830,000 shares. Based on an average trading volume of 257,900 shares, the short-interest ratio is currently 7.5 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on CTSO shares. HC Wainwright reiterated a "neutral" rating and set a $1.00 price target on shares of Cytosorbents in a research report on Monday, November 11th. D. Boral Capital reiterated a "buy" rating and set a $10.00 price target on shares of Cytosorbents in a research report on Monday, January 13th. Finally, StockNews.com assumed coverage on shares of Cytosorbents in a research report on Friday, February 14th. They set a "hold" rating for the company. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $4.67.

Cytosorbents Price Performance

Shares of NASDAQ CTSO remained flat at $1.15 during midday trading on Friday. 82,341 shares of the stock traded hands, compared to its average volume of 366,469. The company's 50-day moving average price is $1.01 and its two-hundred day moving average price is $1.04. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.61. The stock has a market capitalization of $62.88 million, a price-to-earnings ratio of -3.19 and a beta of 0.61.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CTSO. Millennium Management LLC purchased a new position in Cytosorbents in the fourth quarter worth approximately $30,000. Renaissance Technologies LLC lifted its stake in Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock worth $80,000 after acquiring an additional 8,400 shares during the last quarter. Northern Trust Corp lifted its stake in Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after acquiring an additional 16,701 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Cytosorbents in the fourth quarter worth approximately $99,000. Finally, Geode Capital Management LLC lifted its stake in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after acquiring an additional 32,415 shares during the last quarter. Hedge funds and other institutional investors own 32.87% of the company's stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.